Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
Crossref DOI link: https://doi.org/10.1007/s00280-015-2870-0
Published Online: 2015-09-25
Published Print: 2015-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamazaki, N.
Uhara, H.
Fukushima, S.
Uchi, H.
Shibagaki, N.
Kiyohara, Y.
Tsutsumida, A.
Namikawa, K.
Okuyama, R.
Otsuka, Y.
Tokudome, T.
License valid from 2015-09-25